Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Safety, Tolerability, and Pharmacokinetics of ADB116 for Injection in Healthy Chinese Adults: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Phase I Clinical Trial

NCT07729839 is registered in ClinicalTrials.gov with Jiangsu Aidea Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07729839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Safety, Tolerability, and Pharmacokinetics of ADB116 for Injection in Healthy Chinese Adults: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Phase I Clinical Trial
Lead sponsor
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 31, 2026
Completion date
March 18, 2027
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants